^
    Back
    Association details:
    Biomarker:SDC4-ROS1 fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:SIM1803-1A (ROS1 inhibitor, Trk inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2020
    Title:

    Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.

    Published date:
    05/28/2020
    Excerpt:
    SIM1803-1A showed...high efficacy in the subcutaneous NSCLC LU-01-0414 SDC4-ROS1 PDX model with 60% and 74% TGI at 1 and 3 mg/kg (bid) dosing.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e21663